Drug Topics

JUNE 11, 2025

announced that all current members of the CDC's Advisory Committee for Immunization Practices (ACIP) will be retired and replaced in order to “reestablish public confidence in vaccine science.” 2 Noel Brewer, PhD, states that the Advisory Committee of Immunization Practices will need to quickly work to regain trust. Kennedy Jr.

Immunization

Pharmaceutical Technology

JUNE 10, 2025

The US department of Health and Human Services (HHS) has culled the 17 Biden-appointed members on the Advisory Committee for Immunization Practices (ACIP) at the Centers for Disease Control and Prevention (CDC) in a move observers warn is liable to further fuel the spread of vaccine-preventable illnesses. lev radin via Shutterstock.

Vaccines

STAT

NOVEMBER 19, 2024

patent expires in 2028. Keytruda is a cancer immunotherapy, which stimulates the immune system to attack tumor cells and is the best-selling medicine in the world. The subcutaneous injection could be given in a doctor’s office every six weeks, instead of requiring a 30-minute IV drip at the same interval.

Pharmaceutical Companies

Pharmaceutical Technology

AUGUST 8, 2025

With GlobalData currently forecasting that the data and analytics market in pharma will reach $2.1bn by 2028, real-world data is becoming essential to healthcare research. With the data and analytics market in pharmaceuticals now set to be worth $2.1bn by 2028, data needs to be integrated meaningfully to change healthcare outcomes.

Patient Care

European Pharmaceutical Review

DECEMBER 1, 2022

According to GlobalData’s recent report , a total of five marketed messenger RNA (mRNA) non-vaccine products by 2028 will generate over $2 billion, generated by the approval of pipeline agents. billion during 2028.

Vaccines

STAT

JANUARY 8, 2024

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. That could come as soon as 2028. Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors.

Immunization

Pharmaceutical Technology

AUGUST 16, 2022

Enhertu has already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma, with annual sales for these indications alone expected to exceed $1.3bn by 2028.

Chemotherapy

Pharmaceutical Technology

AUGUST 12, 2022

Adoptive cell therapy (ACT) is a form of cancer treatment that involves the transfer of immune cells into a patient to help fight the disease, by eliminating cancer cells. By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. billion in 2021 and is forecast to reach $2.4

Immunization

Pharmaceutical Technology

AUGUST 24, 2022

More than three decades ago, scientists at the National Cancer Institute began exploring ways to fight cancer using the patient’s immune system. CAGR between 2020 and 2028. CAGR between 2020 and 2028. Their work formed the basis of what is now a promising cancer treatment that doesn’t require surgery or radiation.

Method Validation

Pharmaceutical Technology

OCTOBER 28, 2022

What’s more, VAX-24 achieved a higher immune response to 16 of the 20 serotypes it shares with Prevnar 20. billion and $812 million in 2028. On October 26, Vaxcyte stated that this offering was expected to yield approximately $600 million in gross proceeds The company now has a market cap of $2.47 Further plans in the making.

Vaccines

Hospital Pharmacy Europe

JULY 26, 2024

From 2028 the vaccine will be offered to those turning 65 and 60, the letter from NHS England and the UK Health Security Agency set out at the time. Is it through suppression of virus, or is the induced immune response targeting a step in the molecular pathology of Alzheimer’s disease?’

Vaccines

Pharmaceutical Technology

FEBRUARY 13, 2023

GlobalData’s analyst consensus forecast database estimates peak annual sales for ARV-110 of $325 million in 2028. However, on-target adverse events are also common with BTKis as they inhibit B-cell immune responses, which can result in serious infections. with Calquence, 16% with Imbruvica, NCT02477696).

Chemotherapy

Roots Analysis

OCTOBER 4, 2023

They are designed to recognize and bind to two specific molecules, such as a tumor cell and an immune cell, or two different parts of the same molecule. Bispecific antibodies are a type of antibody that can bind to two different targets at the same time.

Chemotherapy

European Pharmaceutical Review

FEBRUARY 14, 2023

Initially developed to treat viral infections, mRNA vaccines deliver a piece of genetic material that instructs the body to make a protein fragment of a target pathogen (such as a virus), which the immune system recognises and remembers 1 to respond to when exposed to the pathogen in the future.

Vaccines

European Pharmaceutical Review

NOVEMBER 1, 2023

Pneumococcal Vaccines Market Size & Share Analysis – Growth Trends & Forecasts 2023-2028. The current state of immunization against Gram-negative bacteria in children: a review of the literature. 2022 [cited May2023], Available from: [link] Murray CJ, Ikuta KS, Sharara F, et al. The Lancet. 2022; 399(10325): 629–55.

Vaccines

pharmaphorum

SEPTEMBER 13, 2022

Crucially, he observed a connection between certain tumours and inflammation, noting that neoplastic tissues were often covered with leukocytes of the immune system. Building on the success of cytokine-based immunotherapies, scientists continued to seek other areas where the immune system could be leveraged against tumours.

Chemotherapy

Pharmaceutical Technology

MAY 26, 2023

was powered by the advent of immune-checkpoint inhibitors, added Chalk. These figures are only expected to grow in the coming years, with sales forecasted to reach over $150 billion by 2028. Checkpoint modulators, cytokines and oncolytic viruses are also considered as part of the overall immune-oncology field.

Immunization

PharmaShots

JUNE 1, 2023

We are very pleased to demonstrate that our innovative immunotherapy platform can induce a strong immune response in humans. We reported at ESMO-IO the analysis of immune response of the first 3 cohorts of patients. Anti-PD-1 antibodies have recently become standard first-line treatments for melanoma and NSCLC. 2015; Zhu et al.,

Immunization

Drug Topics

JUNE 10, 2025

Removes All Members of CDC’s Advisory Committee for Immunization Practices June 10, 2025 By Ashley Gallagher News Article The move follows the announcement of updated COVID-19 vaccine recommendations, which was announced on X. Secretary of Health and Human Services Robert F. Kennedy Jr. 5 This is a developing story. Check back for updates.

Immunization